- Recruiting
NCT04521335: Phase 1: Study of Disulfiram and Copper Gluconate in Patients With RRMM (Repurpose-1)
Updated: Sep 2, 2022
(Repurpose-1)
NCT04521335: Phase 1: Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma (Repurpose-1)

This is a phase I, open-label trial of disulfiram in combination with copper gluconate in patients with treatment-refractory multiple myeloma. The trial is designed to assess the Phase 2 Recommended Dose (RP2D) of disulfiram and copper gluconate in combination. The trial will open with dose escalation, followed to an expansion cohort to further characterize the safety and tolerance of the combination.
Sponsor
University of Utah
Collaborator
ClinicalTrials.gov Identifier: NCT04521335
Official Title: A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
First Posted : August 20, 2020
Click here for details on ClinicalTrials.gov
Disulfiram (Code C447)
Antabuse
Bis(diethylthiocarbamoyl) Disulfide
Disulfiram
DISULFIRAM
disulfiram
DS
Tetraethylthioperoxydicarbonic Diamide
Tetraethylthiuram Disulfide
Teturamin
TTD
Copper Gluconate (Code C80050)
Copper Gluconate
COPPER GLUCONATE
Cupric Gluconate
Drug: Disulfiram
Drug: Copper Gluconate
Location
United States, Utah